Defunct Company
Total Trials
11
As Lead Sponsor
6
As Collaborator
5
Total Enrollment
1,338
NCT03873883
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 5, 2019
Completion: May 28, 2024
NCT04335253
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
Start: Feb 18, 2020
Completion: Apr 7, 2022
NCT04446351
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Role: Collaborator
Start: Jun 25, 2020
Completion: Dec 31, 2025
NCT05117177
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
Start: Jul 1, 2021
Completion: May 9, 2024
NCT05060432
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Phase: Phase 1/2
Start: Sep 6, 2021
Completion: Jul 31, 2025
NCT05289492
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Start: May 1, 2022
Completion: Nov 29, 2023
NCT05403385
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Phase: Phase 2
Start: Aug 26, 2022
Completion: Oct 31, 2025
NCT05565378
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Start: Oct 14, 2022
Completion: Feb 26, 2027
NCT06547957
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
Start: Jul 7, 2023
NCT06062420
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Start: Nov 14, 2023
Completion: Jul 27, 2027
NCT06472076
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Phase: Phase 3
Start: Jun 10, 2024
Completion: Feb 2, 2027